Merck Unusual Options Activity Signals Bullish Bets as Stock Trades Near $111
By TrendSpider Editor
Unusual options activity in Merck & Company, Inc. is drawing attention Tuesday, with four flagged contracts generating a combined total premium of $1,507,614.90. The largest single contract, a $1,116,417.90 call sweep at a $110 strike expiring January 15, 2027, dominates the flow and suggests at
Merck Unusual Options Activity Signals Bullish Bets as Stock Trades Near $111
Unusual options activity in Merck & Company, Inc. is drawing attention Tuesday, with four flagged contracts generating a combined total premium of $1,507,614.90. The largest single contract, a $1,116,417.90 call sweep at a $110 strike expiring January 15, 2027, dominates the flow and suggests at least some institutional players are positioning for continued upside. At a current price of $111.49, MRK sits well above its 52-week low of $73.31 but still has room to run before testing its 52-week high of $125.14.
Key Drivers of the MRK Stock Move
- Main Catalyst: Four unusual options contracts were flagged today with a combined premium of $1,507,614.90. Three of the four contracts are calls, including a deep-volume CALL at $110 strike expiring January 15, 2027 carrying $1,116,417.90 in premium, a CALL at $106 strike expiring May 15, 2026 with 1,000% above open interest, and a longer-dated CALL at $155 strike expiring June 17, 2027 with open interest running at 1,220% above normal.
- Bull Case: The sheer concentration of call premium, led by the $1,116,417.90 January 2027 in-the-money contract, along with the $155 strike call that sits 1,220% above open interest, points to aggressive positioning for MRK to sustain and extend gains well beyond its current price of $111.49. The stock is already up 1.13% on the session.
- Bear Case: A single put contract at the $100 strike expiring June 18, 2026 carried a premium of $182,487 with volume at 1,031 contracts, suggesting at least some traders are hedging against a pullback toward $100, which would represent a significant decline from current levels. The put's open interest reading of only 18% above baseline implies it may reflect fresh positioning rather than a continuation of an existing trend.
The forward setup for MRK looks constructive based on today's options flow, with the weight of premium and contract count tilted decisively toward the call side. The January 2027 in-the-money call at $110 in particular reflects a willingness to pay for long-dated exposure with MRK already trading above that strike, suggesting confidence in the stock holding current levels or pushing higher over the next several quarters. The outlier $155 call expiring June 2027 is deeply out of the money but registered 1,220% of open interest, a signal that is hard to ignore even if the target appears aggressive relative to the 52-week high of $125.14. MRK's recovery from its 52-week low of $73.31 has been substantial, and today's options flow suggests smart money may be anticipating another leg higher.
MRK Unusual Options Activity
- Contract 1: CALL | Strike: $106 | Expiry: May 15, 2026 | Volume: 77 | Open Interest: 1,000% above baseline | In the Money | Premium: $56,210
- Contract 2: PUT | Strike: $100 | Expiry: June 18, 2026 | Volume: 1,031 | Open Interest: 18% above baseline | Out of the Money | Premium: $182,487
- Contract 3: CALL | Strike: $110 | Expiry: January 15, 2027 | Volume: 879 | Open Interest: 60% above baseline | In the Money | Premium: $1,116,417.90
- Contract 4: CALL | Strike: $155 | Expiry: June 17, 2027 | Volume: 500 | Open Interest: 1,220% above baseline | Out of the Money | Premium: $152,500
MRK Seasonality
Late April and early May historically represent an active period for pharmaceutical stocks as first-quarter earnings results and pipeline updates come into focus. With MRK trading near $111.49 heading into the final days of April 2026, options positioning that extends into mid-2027 may reflect expectations tied to key drug approvals or clinical data catalysts expected over the coming year.
MRK Relative Performance
MRK's 1.13% gain on Tuesday puts it in positive territory on the session. With the stock sitting at $111.49 against a 52-week range of $73.31 to $125.14, it has recovered a substantial portion of its prior drawdown, though it remains roughly 10.9% below its one-year high, leaving meaningful upside before the stock would challenge that level again.